Compare Stocks: MDCX, CLNN, CING, and MNOV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$5.21 +0.2%	$4.91	$3.16 ▼ $11.89	$70.04M	-0.9	156,906 shs	85,345 shs
CLNN Clene	$4.07 -6.9%	$5.66	$3.50 ▼ $13.50	$55.84M	0.96	80,776 shs	165,390 shs
MDCX Medicus Pharma	$0.33 -4.3%	$0.37	$0.25 ▼ $3.05	$19.59M	0.11	1.71 million shs	1.10 million shs
MNOV MediciNova	$1.33 +0.8%	$1.34	$1.17 ▼ $1.96	$64.97M	0.63	38,033 shs	13,117 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	-0.95%	+6.12%	+5.91%	+5.69%	+28.40%
CLNN Clene	-15.31%	-17.23%	-30.30%	-32.77%	+14.40%
MDCX Medicus Pharma	+7.52%	+13.75%	-15.16%	+8.03%	-82.45%
MNOV MediciNova	0.00%	+1.54%	-5.04%	-3.65%	-0.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$5.21 +0.2%	$4.91	$3.16 ▼ $11.89	$70.04M	-0.9	156,906 shs	85,345 shs
CLNN Clene	$4.07 -6.9%	$5.66	$3.50 ▼ $13.50	$55.84M	0.96	80,776 shs	165,390 shs
MDCX Medicus Pharma	$0.33 -4.3%	$0.37	$0.25 ▼ $3.05	$19.59M	0.11	1.71 million shs	1.10 million shs
MNOV MediciNova	$1.33 +0.8%	$1.34	$1.17 ▼ $1.96	$64.97M	0.63	38,033 shs	13,117 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	-0.95%	+6.12%	+5.91%	+5.69%	+28.40%
CLNN Clene	-15.31%	-17.23%	-30.30%	-32.77%	+14.40%
MDCX Medicus Pharma	+7.52%	+13.75%	-15.16%	+8.03%	-82.45%
MNOV MediciNova	0.00%	+1.54%	-5.04%	-3.65%	-0.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	2.50	Moderate Buy	$27.33	424.63% Upside
CLNN Clene	2.71	Moderate Buy	$33.25	716.95% Upside
MDCX Medicus Pharma	2.40	Hold	$9.00	2,618.21% Upside
MNOV MediciNova	2.67	Moderate Buy	$8.33	526.57% Upside

Current Analyst Ratings Breakdown

Latest MDCX, CLNN, CING, and MNOV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/24/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/9/2026	CING Cingulate	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/26/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	MNOV MediciNova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/8/2026	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$55.00 ➝ $52.00

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	$0.31 per share	N/A
CLNN Clene	$200K	260.07	N/A	N/A	($1.62) per share	-2.51
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	$410K	159.66	N/A	N/A	$0.85 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$22.45M	-$4.23	N/A	N/A	N/A	N/A	-365.15%	-158.55%	8/18/2026 (Estimated)
CLNN Clene	-$26.17M	-$3.20	N/A	N/A	N/A	-25,009.70%	N/A	-137.98%	8/13/2026 (Estimated)
MDCX Medicus Pharma	-$35.46M	-$2.68	N/A	N/A	N/A	N/A	-3,137.84%	-311.33%	N/A
MNOV MediciNova	-$12M	-$0.23	N/A	N/A	N/A	-1,962.98%	-27.28%	-25.24%	8/13/2026 (Estimated)

Latest MDCX, CLNN, CING, and MNOV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	CING Cingulate	-$0.63	N/A	N/A	N/A	$0.17 million	N/A
8/13/2026	Q2 2026	CLNN Clene	-$0.37	N/A	N/A	N/A	$0.06 million	N/A
8/13/2026	Q2 2026	MNOV MediciNova	-$0.06	N/A	N/A	N/A	$0.08 million	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.14	-$0.21	-$0.07	-$0.21	N/A	N/A
5/14/2026	Q1 2026	CING Cingulate	-$0.53	-$0.95	-$0.42	-$0.95	N/A	N/A
5/14/2026	Q1 2026	CLNN Clene	-$0.6367	-$0.69	-$0.0533	-$0.69	$0.05 million	$0.02 million
5/14/2026	Q1 2026	MDCX Medicus Pharma	-$0.18	-$0.31	-$0.13	-$0.31	N/A	N/A
5/14/2026	Q1 2026	MNOV MediciNova	-$0.06	-$0.05	+$0.01	-$0.05	$0.19 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	2.55	2.55
CLNN Clene	N/A	1.94	1.93
MDCX Medicus Pharma	N/A	1.22	1.22
MNOV MediciNova	N/A	9.09	9.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
CLNN Clene	23.28%
MDCX Medicus Pharma	N/A
MNOV MediciNova	9.90%

Insider Ownership

Company	Insider Ownership
CING Cingulate	5.30%
CLNN Clene	28.30%
MDCX Medicus Pharma	8.10%
MNOV MediciNova	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	20	13.47 million	12.76 million	Not Optionable
CLNN Clene	100	12.78 million	9.16 million	No Data
MDCX Medicus Pharma	N/A	56.66 million	52.07 million	N/A
MNOV MediciNova	10	49.22 million	42.33 million	Optionable

MDCX, CLNN, CING, and MNOV Headlines

Recent News About These Companies

MediciNova (MNOV) Expected to Release Earnings on Thursday

August 6, 2026 | americanbankingnews.com

MediciNova (MNOV) Projected to Release Earnings on Thursday

August 6, 2026 | marketbeat.com

MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by Analysts

July 26, 2026 | marketbeat.com

MediciNova, Inc. (NASDAQ:MNOV) Sees Significant Increase in Short Interest

July 16, 2026 | marketbeat.com

MediciNova Achieves Full Enrollment in NIH-Funded SEANOBI-ALS Study of MN-166 (Ibudilast) for ALS

July 15, 2026 | quiverquant.comQ

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

July 15, 2026 | globenewswire.com

MediciNova CEO Provides Shareholder Update

June 30, 2026 | globenewswire.com

MediciNova Shareholders Reject Proposal to Increase Authorized Stock

June 24, 2026 | tipranks.com

MNOV Share News Today

June 21, 2026 | uk.investing.com

MediciNova (MNOV) Stock Forecast & Price Target

June 11, 2026 | investing.com

MediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026 | finanznachrichten.de

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026 | globenewswire.com

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical ...

May 26, 2026 | caledonianrecord.comC

MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes

May 26, 2026 | quiverquant.comQ

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

May 26, 2026 | globenewswire.com

MediciNova Announces New Insights on Brain Metastasis Vulnerability and Potential Therapeutic Strategies from CNIO Study

April 27, 2026 | quiverquant.comQ

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

April 27, 2026 | globenewswire.com

HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation

March 17, 2026 | msn.com

MediciNova to Participate at the 38th Annual ROTH Conference

March 16, 2026 | globenewswire.com

MediciNova: Q4 Earnings Snapshot

February 20, 2026 | wtop.comW

MediciNova (MNOV) price target increased by 28.57% to 9.18

February 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDCX, CLNN, CING, and MNOV Company Descriptions

Cingulate NASDAQ:CING

$5.21 +0.01 (+0.19%)

As of 04:00 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Clene NASDAQ:CLNN

$4.07 -0.30 (-6.86%)

As of 04:00 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Medicus Pharma NASDAQ:MDCX

$0.33 -0.01 (-4.25%)

As of 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

MediciNova NASDAQ:MNOV

$1.33 +0.01 (+0.76%)

As of 04:00 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDCX, CLNN, CING, and MNOV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDCX, CLNN, CING, and MNOV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDCX, CLNN, CING, and MNOV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDCX, CLNN, CING, and MNOV Company Descriptions

Cingulate NASDAQ:CING

Clene NASDAQ:CLNN

Medicus Pharma NASDAQ:MDCX

MediciNova NASDAQ:MNOV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDCX, CLNN, CING, and MNOV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDCX, CLNN, CING, and MNOV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDCX, CLNN, CING, and MNOV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDCX, CLNN, CING, and MNOV Company Descriptions

Cingulate NASDAQ:CING

Clene NASDAQ:CLNN

Medicus Pharma NASDAQ:MDCX

MediciNova NASDAQ:MNOV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools